The influence of antimalarials on lipids in systemic lupus erythematosus (SLE) has been identified in several studies but not in many prospective cohorts. The aim of this study was to longitudinally determine the effect of antimalarials on the lipoprotein profile in SLE. Patients and methods: Fasting total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein cholesterol (LDL) plasma levels were determined at entry and after 3 months of hydroxychloroquine (HCQ) treatment in a longitudinal evaluation of 24 patients with SLE. Results: a significant decrease in TC (198 AE 33.7 vs. 183 AE 30.3 mg/dl, p ¼ 0.023) and LDL levels (117 AE 31.3 vs. 101 AE 26.2 mg/dl, p ¼ 0.023) were detected after the 3 months of HCQ therapy. The reduction of 7.6% in TC (p ¼ 0.055) and 13.7% in LDL levels (p ¼ 0.036) determined a significant decrease in the frequency of dyslipidemia (26% vs. 12.5%, p ¼ 0.013) after HCQ therapy. Conclusion: This longitudinal study demonstrated the beneficial effect of antimalarials on lipids in SLE since this therapy induced a reduction of atherogenic lipoproteins. Lupus (2012) 21, 1178-1182.
Introduction
Atherosclerosis has been increasingly recognized as an important cause of morbidity and mortality in systemic lupus erythematosus (SLE), and the role of cardiovascular risk factors has been clearly documented. 1, 2 There is strong evidence supporting the notion that the development of atherosclerosis in SLE involves traditional and nontraditional risk factors. 2 Autoimmunity and inflammation are associated with marked changes in lipoprotein metabolism in SLE which includes several mechanisms, 3, 4 but seems closely related to disease activity. 5, 6 Indeed, definitive evidence for primary abnormalities of lipoprotein metabolism due to SLE was recognized as the 'lupus pattern' of dyslipoproteinemia that was characterized by increased levels of very low-density lipoprotein cholesterol and triglycerides and reduced high-density lipoprotein (HDL) cholesterol levels. 6, 7 The antimalarials chloroquine diphosphate and hydroxychloroquine (HCQ) are currently used for the management of SLE and may have an important role in reducing atherosclerosis and mortality in this disease. 8, 9 A wide variety of other beneficial effects have been associated with the use of antimalarials, which makes this drug regimen the cornerstone of the lupus therapy. 8, 10 The influence of antimalarials on the lipid profile in SLE has been suggested in several studies, [11] [12] [13] [14] [15] but most of them were carried out in prospective cohorts of patients with SLE using a cross-sectional design, which might explain differences in their results. 8 In fact, only one study with a limited number of patients with SLE longitudinally analyzed the effect of antimalarials in the lipid profile. 16 Therefore, the aim of this study was to prospectively determine the lipidlowering effect on lipoproteins in patients with SLE after 3 months of HCQ use.
Patients and methods
Twenty-four consecutive patients with SLE were selected among the Unit of Systemic Autoimmune Disease, Clı´nica Me´dica ''C'', Hospital de Clı´nicas, Universidad de la Repu´blica, Uruguay. All patients fulfilled four or more of the revised classification criteria for SLE of the American College of Rheumatology. 17 Exclusion criteria were evidence of diabetes mellitus, clinical or subclinical thyroid disease, liver disease, nephritis (active renal disease, uremia, and/or nephrotic syndrome), and current use of any lipid-lowering drugs. Overall clinical activity was measured according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), 18 and all patients had minor disease activity (SLEDAI scores <5) at entry and after 3 months of HCQ therapy. Clinical and laboratory data were prospectively collected and recorded on a standard form, including current therapy. To analyze possible effects of HCQ on the lipid profile, 24 patients with SLE without this therapy and who would be initiated were selected. Lipoproteins were determined at entry and after 3 months of HCQ therapy (daily dose 200 mg) for this followup evaluation. Clinical data, laboratory data and therapy were also recorded. The study was approved by the local Ethics Committee and informed consent was obtained from all participants.
Lipid measurements
At entry, patients with SLE were on their normal diet and had been fasting for at least 12 h. Lipoproteins were measured in the biochemistry laboratory using an automated analyzer, which uses dry slide chemistry technology. Fasting total cholesterol (TC), triglycerides (TG), and HDL plasma levels were determined. Low-density lipoprotein cholesterol levels (LDL) were estimated using the equation: 19 
Lipoprotein risk levels
Cardiovascular risk level was defined according to the criteria of the National Cholesterol Education Program (NCEP) guidelines for adults, 20 as follows: TC > 200 mg/dl, TG > 150 mg/dl, HDLc < than 40 mg/dl, and LDL-c > 130 mg/dl.
Statistical analysis
Results are presented as the mean AE standard deviation (SD). Comparison between the different groups was performed using paired Student t-test and Mann-Whitney U Test. Association analyses were performed using chi-squared test and Fisher's exact test when appropriate (for optimal levels of TC and LDL below 200 mg% and 130 mg%, respectively). In order to analyze possible confounding effect of steroids, a linear regression analysis was developed considering differences (delta) between lipoprotein levels (dependent variable) and prednisone dose (independent variable) before and after HCQ treatment. A p-value <0.05 was considered statistically significant.
Results
At entry, the mean age of the 24 patients with SLE was 37.2 AE 16 years with mean disease duration of 6.5 AE 8 years. Most of these patients were female (95.8%) with a predominance of white ethnicity (62.5%). The mean weight was 70.1 AE 14.8 kg, height 1.60 AE 0.08 m, and body mass index 27.1 AE 5.8 kg/m 2 . All patients had positive antinuclear antibodies and 79.2% had anti-dsDNA antibodies. At the time of the study, 13 patients with SLE were using steroids (54.1%) with a mean prednisone dose of 13.3 AE 16 mg/day. Four patients (16.6%) were on azathioprine therapy.
Longitudinal lipoprotein evaluation
The lipid profile of the 24 patients with SLE was determined at entry and after 3 months of HCQ therapy for this follow-up evaluation. A significant decrease in TC and LDL levels was observed after 3 months of HCQ (p ¼ 0.023 and p ¼ 0.023, respectively) ( Table 1) . A decrease of 7.6% in TC and 13.7% in LDL levels (mean decrease of 15 mg/dl and 16 mg/dl, respectively) was detected after this therapy. The apparent low percentage of patients with TC levels >200 mg/dl after HCQ use did not reach statistical significance compared with entry, although a decreasing trend was observed (41.6% vs. 16.6%, p ¼ 0.055). On the other hand, a significant decrease was observed in the percentage of LDL levels >130 mg/dl (33.3% vs. 8.3%, p ¼ 0.036) ( Table 1) .
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A significant reduction in the daily prednisone dose was also observed during the follow-up study (13.3 AE 16 vs. 6.7 AE 9.1 mg/day, p ¼ 0.025) ( Table 1 ). This reduction in the prednisone dose was approximately half of the initial dose. In order to analyze a possible confounding effect of change in steroid dose, a linear regression analysis was performed. No significant association between the reduction of prednisone dose and the decreased of TC and LDL levels was observed (p ¼ 0.666). Of the 11 patients without prednisone at the time of inclusion, only six did not receive prednisone at follow-up (at entry and after 3 months of receiving HCQ). In these patients, we found a significant decrease in LDL levels (p ¼ 0.021), where the values before and after use of HCQ were 118 AE 25 mg/dl and 105 AE 24 mg/dl, respectively. Although the levels of TC, TG and HDL had a decrease tendency, the differences were not statistically significant.
At the final evaluation, the frequency of dyslipidemia was significantly lower after the 3 months of HCQ (26.0 % vs. 12.5 %, p ¼ 0.013) ( Table 1) .
Discussion
This study clearly demonstrated the favorable effect of HCQ on the lipid profile in patients with SLE, since a decrease in TC and LDL levels was observed in the longitudinal evaluation.
To achieve these findings, rigorous selection criteria were established to exclude other conditions that promote specific alterations in lipid metabolism. [21] [22] [23] [24] [25] Moreover, all patients included in the study had inactive disease, since it is known that activity can aggravate lupus dyslipoproteinemia, 5, 6 and were not using drugs that could interfere with lipoprotein metabolism. 26 It was also important to consider the duration of HCQ therapy to accurately define its influence on the lipid profile. Of note, changes in lipoproteins were detected after 3 months of antimalarial treatment and became stable after 12 months. 11, 12, 14 Regarding prednisone use, use of stable doses for at least 1 month prior to evaluation was another important issue to determine the effect of this drug on lipid metabolism. 7, 27 The great advantage of the present study was to identify a significant reduction of TC and LDL levels in patients with SLE in a longitudinal evaluation after HCQ therapy. Indeed, in our study, patients with SLE receiving HCQ had 7.6% lower TC and 13.7% lower LDL levels, which is in accordance with the finding of an 8.5% decrease in serum cholesterol described previously in a cohort study. 15 In SLE, it has previously been demonstrated that HCQ use elicits lower LDL cholesterol levels, particularly in patients taking corticosteroids. 15, 28 In fact, Wallace et al. were the first to demonstrate the beneficial impact of HCQ on the lipid profile in a cohort of patients with SLE. 28 Thereafter, with the exception of one Chinese study, 29 all studies have supported the finding that antimalarials do indeed decrease TC in patients with SLE receiving steroids, and minimize steroid-induced hypercholesterolemia. 11, 12, 14, 30 The known increase in lipoprotein hepatic synthesis induced by steroids 7, 27, [31] [32] [33] may be counterbalanced by antimalarial-enhanced removal of LDL. In fact, it was recently suggested that antimalarials up-regulate LDL receptors, increasing the in vivo plasma kinetics of cholesterol-rich emulsion in SLE. 11 This effect was strong enough to produce a 20% reduction in the LDL levels after this therapy. 11 This possibility was confirmed in our 3month follow-up evaluation of the 24 patients with SLE after receiving HCQ, since we observed a significant decrease in TC and LDL levels in parallel with the daily prednisone dose. Moreover, in randomized trials in diabetic patients after the use of HCQ, a decrease in LDL levels was also identified. 34, 35 Therefore, these results support the notion that even short-term use of HCQ has a beneficial effect on lipids, particularly in the reduction of TC and LDL levels, and might also help to reduce the cardiovascular risk in SLE. 
